Skip to content

Citius Oncology, Inc. CTOR Warrants and Rights Outstanding

Warrants and Rights Outstanding at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s warrants and rights outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s warrants and rights outstanding?
Citius Oncology, Inc. (CTOR) reported warrants and rights outstanding of 816.7K in Q4 2025.
What does warrants and rights outstanding mean?
This metric represents the total number of outstanding warrants and rights that grant holders the option to purchase company equity at a specified price. It serves as a measure of potential future dilution for existing shareholders. Investors monitor this to assess the impact of potential equity issuance on earnings per share and overall ownership structure.